Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer

NCT04293276 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

41

Enrollment

OTHER_GOV

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Pyrotinib
DRUG: SHR6390

Sponsor

Henan Cancer Hospital

Collaborators

[object Object]